Pushkar Saralkar
Overview
Explore the profile of Pushkar Saralkar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vijikumar A, Saralkar P, Saylor S, Sullivan P, Huber J, Geldenhuys W
Exp Neurol
. 2022 Jun;
355:114128.
PMID: 35662609
Cerebral ischemic stroke is a leading cause of mortality and disability worldwide. Currently, there are a lack of drugs capable of reducing neuronal cell loss due to ischemia/reperfusion-injury after stroke....
2.
Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo
Liu Z, Shah N, Marshall K, Sprowls S, Saralkar P, Mohammad A, et al.
Arch Toxicol
. 2021 Aug;
95(11):3575-3587.
PMID: 34455456
In our previous work, PC-9-Br, a PC-9 brain seeking line established via a preclinical animal model of lung cancer brain metastasis (LCBM), exhibited not only resistance to epidermal growth factor...
3.
Sprowls S, Saralkar P, Arsiwala T, Adkins C, Blethen K, Pizzuti V, et al.
Pharmaceutics
. 2021 Jun;
13(5).
PMID: 34069733
The blood-brain barrier (BBB) limits movement of solutes from the lumen of the brain microvascular capillary system into the parenchyma. The unidirectional transfer constant, , is the rate at which...
4.
Saralkar P, Mdzinarishvili A, Arsiwala T, Lee Y, Sullivan P, Pinti M, et al.
Pharm Res
. 2021 May;
38(5):803-817.
PMID: 33982226
Purpose: Therapeutic strategies to treat ischemic stroke are limited due to the heterogeneity of cerebral ischemic injury and the mechanisms that contribute to the cell death. Since oxidative stress is...
5.
Butler C, Sprowls S, Szalai G, Arsiwala T, Saralkar P, Straight B, et al.
Transl Oncol
. 2020 May;
13(6):100775.
PMID: 32408199
Breast cancer patients presenting with symptomatic brain metastases have poor prognosis, and current chemotherapeutic agents are largely ineffective. In this study, we evaluated the hypomethylating agent azacitidine (AZA) for its...
6.
Geldenhuys W, Long T, Saralkar P, Iwasaki T, Nunez R, Nair R, et al.
Commun Chem
. 2020 May;
2.
PMID: 32382661
MitoNEET (gene ) is a mitochondrial outer membrane [2Fe-2S] protein and is a potential drug target in several metabolic diseases. Previous studies have demonstrated that mitoNEET functions as a redox-active...
7.
Saralkar P, Arsiwala T, Geldenhuys W
Int J Pharm
. 2020 Feb;
578:119090.
PMID: 32004683
Ischemic reperfusion injury after a stroke is a leading cause of mortality and disability due to neuronal loss and tissue damage. Mitochondrial dysfunction plays a major role in the reperfusion-injury...
8.
Nair R, Piktel D, Hathaway Q, Rellick S, Thomas P, Saralkar P, et al.
Pharm Res
. 2020 Jan;
37(3):43.
PMID: 31989336
Purpose: Pyrvinium pamoate (PP) is an anthelmintic drug that has been found to have anti-cancer activity in several cancer types. In the present study, we evaluated PP for potential anti-leukemic...
9.
Shah N, Mohammad A, Saralkar P, Sprowls S, Vickers S, John D, et al.
Pharmacol Res
. 2018 Apr;
132:47-68.
PMID: 29604436
In women, breast cancer is the most common cancer diagnosis and second most common cause of cancer death. More than half of breast cancer patients will develop metastases to the...
10.
Sheppard J, Frazier K, Saralkar P, Hossain M, Geldenhuys W, Long T
Bioorg Med Chem Lett
. 2018 Mar;
28(8):1298-1302.
PMID: 29571571
Sixteen disulfides derived from disulfiram (Antabuse™) were evaluated as antibacterial agents. Derivatives with hydrocarbon chains of seven and eight carbons in length exhibited antibacterial activity against Gram-positive Staphylococcus, Streptococcus, Enterococcus,...